Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SGHT vs BMRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SGHT Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–1 Matrix Metrics)

SGHT Overall Winner 6-Pillar Tally: SGHT 3 – 2 BMRA (1 Tie) Matrix Metrics: SGHT 7 – 1 BMRA

As of Nov 16, 2026, Sight Sciences, Inc. (SGHT) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). SGHT carries a Unified Composite Score of 35.1/100 (SELL) at $10.62 (N/M Forward P/E, -20.2% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin).

  • Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. SGHT 35.1/100 SELL), SGHT captures the overall institutional head-to-head verdict (7–1 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-20.2% vs. -125.2% operating margin) and revenue trajectory (+25.2% vs. -8.3% YoY).
  • Technical & Structure Timing Caution: SGHT trades in a Markup technical trend (BREAKOUT options phase, RSI 64.1); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SGHT vs BMRA
SGHT NASDAQ Head-to-Head Winner
Sight Sciences, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$10.62
-1.94% 1D
Market Cap $610.8M
TTM Revenue $88M
Forward P/E N/M
Beta / 30D Vol 1.06β · 46% Vol
Unified Composite Score
35.1 / 100 SELL
Tech 50.0 Fund 32.0 Flow 57.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.0% over 20 days), RSI 64
RSI-14: 64.1 · SMA20: $9.74 · SMA50: $9.01
BMRA NASDAQ
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.33
-2.32% 1D
Market Cap $6.0M
TTM Revenue $4.3M
Forward P/E N/M
Beta / 30D Vol 0.67β · 62% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $1.62 · SMA50: $1.96

6-Pillar Scorecard Institutional Category Breakdown (SGHT 3 – 2 BMRA)

Columns: Metric · SGHT · BMRA
1. Valuation Multiples BMRA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 6.5x 1.1x
2. Growth & Scale SGHT
Revenue Growth (YoY) +25.2% -8.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $88M $4.3M
Market Cap $610.8M $6.0M
3. Profitability & Quality SGHT
Gross Margin 87.7% 0.9%
Operating Margin -20.2% -125.2%
Net Profit Margin -32.1% -115.5%
Return on Equity (ROE) -50.1% -113.8%
4. Balance Sheet & Cash Flow BMRA
Cash Generation (TTM) -$17M -$3.2M
Cash Flow Margin -19.1% -73.5%
Net Cash / Leverage $35M Net Cash $1.1M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SGHT
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 78.7% (8th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SGHT (7) vs BMRA (1)
Institutional Metric SGHT BMRA Criterion Row Edge
Market Capitalization
Scale
$610.8M $6.0M Larger Scale SGHT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+25.2% -8.3% Higher Growth SGHT
Operating Margin (TTM)
Profitability
-20.2% -125.2% Higher Margin SGHT
Net Profit Margin
Profitability
-32.1% -115.5% Higher Margin SGHT
Return on Equity (ROE)
Capital Efficiency
-50.1% -113.8% Higher ROE SGHT
52-Week Range Position
Momentum
88% ($3–$12) 4% ($1–$3) Stronger Trend SGHT
Beta / 30D Volatility
Risk Regime
1.06β · 46% Vol 0.67β · 62% Vol Lower Realized Risk SGHT
Unified Institutional Score
Composite Signal
35.1 / 100 (SELL) 44.5 / 100 (HOLD) Higher Composite BMRA
Trailing 12M Revenue (USD)
Operating Scale
$88M $4.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.7% 0.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.5x EV/Rev N/M PEG · 1.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$17M ($35M Net Cash) -$3.2M ($1.1M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SGHT +56.45 pp
SGHT: +28.26% · BMRA: -28.19%
3M Horizon SGHT +46.17 pp
SGHT: +29.2% · BMRA: -16.97%
6M Horizon SGHT +159.48 pp
SGHT: +118.52% · BMRA: -40.96%
1Y Horizon SGHT +97.5 pp
SGHT: +50.64% · BMRA: -46.86%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SGHT Revenue BMRA Revenue SGHT Op. Margin BMRA Op. Margin Margin Leader
FY2019 N/A $10M N/A -46.4% BMRA
FY2020 $30M $10M -116.5% -41.0% BMRA
FY2021 $50M $10M -105.2% -104.2% BMRA
FY2022 $70M $20M -117.7% -24.0% BMRA
FY2023 $80M $10M -70.7% -135.3% SGHT
FY2024 $80M $10M -63.3% -117.6% SGHT
FY2025 $80M $10M -48.0% -96.7% SGHT
FY2026 N/A $0M N/A -119.5% BMRA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SGHT BREAKOUT
33d in phase · OBV ACCUMULATION
Current IV 78.7%
IV Percentile 8th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact SGHT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BMRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SGHT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $610.8M market capitalization and -20.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BMRA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.0M market capitalization and -125.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SGHT vs BMRA Key Questions & Quantitative Answers

As of Nov 16, 2026, Sight Sciences, Inc. (SGHT) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). SGHT carries a Unified Composite Score of 35.1/100 (SELL) at $10.62 (N/M Forward P/E, -20.2% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin). Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. SGHT 35.1/100 SELL), SGHT captures the overall institutional head-to-head verdict (7–1 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-20.2% vs. -125.2% operating margin) and revenue trajectory (+25.2% vs. -8.3% YoY). Technical & Structure Timing Caution: SGHT trades in a Markup technical trend (BREAKOUT options phase, RSI 64.1); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SGHT leads the Growth & Scale pillar: SGHT posts +25.2% YoY revenue growth and +0.0% YoY earnings growth on $88M TTM revenue (87.7% gross margin, -20.2% operating margin), compared with BMRA at -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), SGHT cumulative revenue shifted +166.7% while BMRA shifted +0.0%. In operating R&D and SG&A reinvestment, SGHT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BMRA.

BMRA screens cheaper on headline valuation multiples. SGHT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.5x EV/Revenue (-19.1% FCF margin), whereas BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SGHT (-50.1% ROE) versus BMRA (-113.8% ROE) capital efficiency.

In options market volatility and institutional positioning, SGHT carries 78.7% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.06β · 46% Vol realized risk). By comparison, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.